Compare Johnson & Johnson (JNJ) vs Rockwell Automation (ROK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Rockwell Automation — how do they compare? Johnson & Johnson trades at $261.41 (market cap $618.09B), while Rockwell Automation trades at $432.38 (market cap $48.21B). The key difference: Johnson & Johnson is far larger — about 12.8× Rockwell Automation's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Rockwell Automation for 74 Days on average.
| JNJ | ROK | |
|---|---|---|
Market Cap | $618.09B | $48.21B |
Volume | 6,050,983 | 953,342 |
Sector | Health | Industrials |
52-Week High | $278.43 | $495.08 |
52-Week Low | $186.00 | $333.75 |
Typical Hold Time | 129 Days | 74 Days |
Enterprise Value | $646.37B | $51.34B |
Dividend Yield | 2.09% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Rockwell Automation (ROK) trades at $432.59, down 2.11% on the day, with a bearish technical signal from moving averages and neutral oscillators. The company shows strong profitability with a 49.09% gross margin and 34.47% ROE, though net income declined to $869M in 2025. Recent news highlights leadership in industrial automation, including partnerships in AI cybersecurity and robotic platforms, supporting positive long-term demand trends.
The stock presents a mixed outlook: analyst consensus targets $489.89 (13% upside) with a majority Hold rating, but high valuation ratios (P/E 40.65) and recent earnings misses pose risks. Key opportunities include automation tailwinds from data centers and labor shortages, while execution on revenue growth and margin stabilization remains critical for shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →
